全文获取类型
收费全文 | 49130篇 |
免费 | 3722篇 |
国内免费 | 111篇 |
专业分类
耳鼻咽喉 | 468篇 |
儿科学 | 1833篇 |
妇产科学 | 1305篇 |
基础医学 | 6117篇 |
口腔科学 | 428篇 |
临床医学 | 6264篇 |
内科学 | 8907篇 |
皮肤病学 | 1002篇 |
神经病学 | 4987篇 |
特种医学 | 961篇 |
外科学 | 5138篇 |
综合类 | 395篇 |
现状与发展 | 1篇 |
一般理论 | 86篇 |
预防医学 | 6936篇 |
眼科学 | 844篇 |
药学 | 3422篇 |
中国医学 | 60篇 |
肿瘤学 | 3809篇 |
出版年
2024年 | 57篇 |
2023年 | 514篇 |
2022年 | 817篇 |
2021年 | 1816篇 |
2020年 | 1108篇 |
2019年 | 1794篇 |
2018年 | 1898篇 |
2017年 | 1460篇 |
2016年 | 1550篇 |
2015年 | 1628篇 |
2014年 | 2290篇 |
2013年 | 2990篇 |
2012年 | 4482篇 |
2011年 | 4405篇 |
2010年 | 2407篇 |
2009年 | 1990篇 |
2008年 | 3451篇 |
2007年 | 3394篇 |
2006年 | 3154篇 |
2005年 | 2955篇 |
2004年 | 2550篇 |
2003年 | 2137篇 |
2002年 | 1862篇 |
2001年 | 210篇 |
2000年 | 137篇 |
1999年 | 216篇 |
1998年 | 301篇 |
1997年 | 217篇 |
1996年 | 175篇 |
1995年 | 155篇 |
1994年 | 114篇 |
1993年 | 99篇 |
1992年 | 66篇 |
1991年 | 46篇 |
1990年 | 49篇 |
1989年 | 51篇 |
1988年 | 35篇 |
1987年 | 28篇 |
1986年 | 30篇 |
1985年 | 31篇 |
1984年 | 37篇 |
1983年 | 37篇 |
1982年 | 16篇 |
1981年 | 21篇 |
1980年 | 21篇 |
1978年 | 20篇 |
1977年 | 15篇 |
1976年 | 15篇 |
1975年 | 19篇 |
1973年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
Andrea Stracciolini Jennifer Luz Gregory Walker Nicholas M. Edwards Avery D. Faigenbaum Gregory D. Myer 《The Physician and sportsmedicine》2020,48(2):199-207
ABSTRACT
Objective
To investigate primary care physician clinical practice patterns, barriers, and education surrounding pediatric physical activity (PA), and to compare practice patterns by discipline. 相似文献12.
13.
14.
15.
16.
17.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
18.
19.
20.
Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. Treatment of CTCL is challenging given the disease states’ varying presentation and prognosis. Systemic treatment options often lack comparative evidence and have relatively low response rates and short duration of response. The recent Food and Drug Administration (FDA) approval of mogamulizumab in adult patients with relapsed or refractory (R/R) CTCL after at least one prior line of therapy provided a new treatment option to patients with advanced disease.
Areas covered: The authors discuss basic information about CTCL and mogamulizumab’s mechanism of action. Then, the authors discuss the agent’s efficacy. Finally, the authors evaluate the safety of mogamulizumab in comparison to other agents available in CTCL.
Expert opinion: Mogamulizumab has been shown to be an effective and well tolerated therapy for patients with relapsed and refractory MF/SS with excellent activity in the circulating component of the disease. 相似文献